Simone Bernardotto

Mr. Simone Bernardotto

University of Padua, Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MAMattia Albiero
Mattia Albiero
AFAlice Fullin
Alice Fullin
GVGianmarco Villano
Gianmarco Villano
ABAlessandra Biasiolo
Alessandra Biasiolo
SQSantina Quarta
Santina Quarta
Margherita MorpurgoMargherita Morpurgo
Margherita Morpurgo
Foot ulcerations are a disabling complication of diabetes and no treatment is currently available based on disease mechanisms. The protein serpin B3 (SB3) was identified as a positive biomarker of successful diabetic wound healing; therefore, its exogenous administration may promote healing. The topical administration of SB3 is challenging due to its protein nature. Physical entrapment in wet sol–gel silica can stabilize the protein’s conformation and permit its sustained delivery. However, irreversible syneresis and poor viscoelastic properties hamper wet sol–gel silica application as a semisolid vehicle. To overcome these limits, a sol–gel silica/hydroxypropylmethylcellulose (HPMC) hydrogel blend was developed. SB3 entrapped in 8% SiO2 wet sol–gel silica preserved its structure, was stabilized against denaturation, and was slowly released for at least three days. Blending a silica gel with an HPMC–glycerol (metolose-G) hydrogel permitted spreadability without affecting the protein’s release kinetics. When administered in vivo, SB3 in silica/metolose-G—but not in solution or in metolose-G alone—accelerated wound healing in SB3 knockout and diabetic mouse models. The results confirmed that SB3 is a new pharmacological option for the treatment of chronic ulcers, especially when formulated in a slow-releasing vehicle. Silica–metolose-G represents a novel type of semisolid dosage form which could also be applied for the formulation of other bioactive proteins.

16 November 2023 in Biomaterials
Verified
Journal Article
Open access
SBSimone Bernardotto
Simone Bernardotto
IFIlaria Frasson
Ilaria Frasson
SFSilvia Faravelli
Silvia Faravelli
AMAnnalisa Morelli
Annalisa Morelli
ESElisa Schiavon
Elisa Schiavon
Margherita MorpurgoMargherita Morpurgo
Margherita Morpurgo
Nanodecoy systems based on analogues of viral cellular receptors assembled onto fluid lipid-based membranes of nano/extravescicles are potential new tools to complement classic therapeutic or preventive antiviral approaches. The need for lipid-based membranes for transmembrane receptor anchorage may pose technical challenges along industrial translation, calling for alternative geometries for receptor multimerization. Here we developed a semisynthetic self-assembling SARS-CoV-2 nanodecoy by multimerizing the biotin labelled virus cell receptor -ACE2- ectodomain onto a poly-avidin nanoparticle (NP) based on the Avidin-Nucleic-Acid-NanoASsembly-ANANAS. The ability of the assembly to prevent SARS-CoV-2 infection in human lung cells and the affinity of the ACE2:viral receptor-binding domain (RBD) interaction were measured at different ACE2:NP ratios. At ACE2:NP = 30, 90 % SARS-CoV-2 infection inhibition at ACE2 nanomolar concentration was registered on both Wuhan and Omicron variants, with ten-fold higher potency than the monomeric protein. Lower and higher ACE2 densities were less efficient suggesting that functional recognition between multi-ligand NPs and multi-receptor virus surfaces requires optimal geometrical relationships. In vivo studies in mice showed that the biodistribution and safety profiles of the nanodecoy are potentially suitable for preventing viral infection upon nasal instillation. Viral receptor multimerization using ANANAS is a convenient process which, in principle, could be rapidly adapted to counteract also other viral infections.

21 May 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
SBSimone Bernardotto
Simone Bernardotto
ECElena Colusso
Elena Colusso
YCYlenia Calogero
Ylenia Calogero
IBIlona Barker
Ilona Barker
EFErica Franceschinis
Erica Franceschinis
Margherita MorpurgoMargherita Morpurgo
Margherita Morpurgo

22 July 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MVMartina Bruna Violatto
Martina Bruna Violatto
MVManuela Vitulo
Manuela Vitulo
ESElisa Schiavon
Elisa Schiavon
CCChiara Caime
Chiara Caime
AMAnnalisa Morelli
Annalisa Morelli
DBDonatella Barisani
Donatella Barisani
Primary biliary cholangitis (PBC) is the most common life-long autoimmune liver disease arising from a biliary epithelial activation to a complex evolving cascade of immune-mediated injury, leading to inflammation and fibrosis and ultimately cirrhosis and liver failure. Ursodeoxycholic acid (UDCA) remains the only first-line treatment, despite being ineffective in approximately 40% of patients. Inadequate response to UDCA has been associated with increased death risk or need for liver transplantation. Starting from these premises, novel or repurposed drugs are currently needed. Immunosuppressive therapies, such as corticosteroids, remain controversial, primarily due to safety concerns related to off-target effects and limited evidence of enhanced efficacy. Nanoparticles are known to accumulate in the liver. Among them, Avidin-Nucleic-Acids-Nano-ASsemblies (ANANAS) have emerged as promising drug carriers thanks to their multi-functionality and convenient tunability, biodegradability, biocompatibility and scalable manufacturing. Despite the availability of numerous PBC models, none replicate key features of human disease to the degree observed in ARE Del-/- mice. Focusing on this model, ANANAS loaded with acid-releasable dexamethasone (ANANAS-Hz-Dex-M) were parenterally administered to evaluate distribution, pharmacokinetics, and therapeutic efficacy. The single treatment demonstrated selective liver tropism with an exclusive steroid release, and interaction with resident macrophages. Multiple administrations significantly reduced hepatic fibrosis. In vitro, isolated Kupffer cells from ARE Del-/- internalize the nanoassembly, with a reduction of the inflammatory profile. Our findings delineate ANANAS-Hz-Dex-M as a tool with the potential to guide resident macrophage plasticity and ameliorate disease course.

30 April 2026 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
SBSimone Bernardotto
Simone Bernardotto
GCGiorgio Crivellaro
Giorgio Crivellaro
MSMattia Schiavo
Mattia Schiavo
ESElisa Schiavon
Elisa Schiavon
MSMartina Stocco
Martina Stocco
Margherita MorpurgoMargherita Morpurgo
Margherita Morpurgo